|
Anaerobes
can infect normal hosts and hosts with compromised resistance or
damaged tissues. Symptoms depend on site of infection. Anaerobes
are often accompanied by aerobic organisms. Diagnosis is clinical
combined with Gram stain and anaerobic cultures. Treatment is with
antibiotics and surgical drainage and debridement.
Hundreds of species of nonsporulating anaerobes are part of the normal flora of the skin, mouth, GI tract, and vagina. If this commensal relationship is disrupted (eg, by surgery, other trauma, poor blood supply, or tissue necrosis), a few of these species can cause infections with high morbidity and mortality. After becoming established in a primary site, organisms can spread hematogenously to distant sites. Because aerobic and anaerobic bacteria are frequently present in the same infected site, appropriate procedures for isolation and culture are necessary to keep from overlooking the anaerobes. Anaerobes can be the main cause of infection in the pleural spaces and lungs; in intra-abdominal, gynecologic, CNS, upper respiratory tract, and cutaneous diseases; and in bacteremia.
Etiology
The principal anaerobic gram-positive cocci that cause disease are peptococci and peptostreptococci, which are part of the normal flora of the mouth, upper respiratory tract, and large intestine. The principal anaerobic gram-negative bacilli include Bacteroides fragilis, Prevotella melaninogenica, and Fusobacterium sp. The B. fragilis group is part of the normal bowel flora and includes the anaerobic pathogens most frequently isolated from intra-abdominal infections. Organisms in the Prevotella group and Fusobacterium sp are part of the normal oral flora.
Pathophysiology
Anaerobic infections can usually be characterized as follows:
Some anaerobic bacteria possess distinct virulence factors. The virulence factors of B. fragilis probably account for its frequent isolation from clinical specimens despite its relative rarity in normal flora. This organism has a polysaccharide capsule that apparently stimulates abscess formation. An experimental model of intra-abdominal sepsis has shown that B.
fragilis alone can cause abscesses, whereas other Bacteroides sp require the synergistic effect of another organism. Another virulence factor, a potent endotoxin, is implicated in septic shock associated with severe Fusobacterium pharyngitis.
Morbidity and mortality rates for anaerobic and mixed bacterial sepsis are as high as those for sepsis caused by a single aerobic organism. Anaerobic infections are often complicated by deep-seated tissue necrosis. The overall mortality rate for severe intra-abdominal sepsis and mixed anaerobic pneumonias tends to be high. B. fragilis bacteremia has a high mortality rate, especially in the elderly and in patients with cancer.
Symptoms and Signs
Patients usually have fever, rigors, and critical illness; shock may develop. DIC may occur in Fusobacterium sepsis.
For specific infections (and symptoms) caused by mixed anaerobic organisms, see elsewhere in The Manual and Table 2: Anaerobic Bacteria: Disorders Often Caused by Mixed* Anaerobic Organisms . Anaerobes are rare in UTI, septic arthritis, and infective endocarditis.
|
Table 2
|
 | | |
|
Disorders Often Caused
by Mixed* Anaerobic Organisms
|
|
Anaerobic cellulitis
|
|
Aspiration pneumonia
|
|
Bartholin's gland infections
|
|
Brain abscesses
|
|
Chronic otitis media
|
|
Chronic sinusitis
|
|
Decubitus or ischemic ulcer infections
|
|
Dental abscesses
|
|
Endometritis
|
|
Epidural and subdural empyema
|
|
Human bite infections
|
|
Intra-abdominal abscess
|
|
Liver abscess
|
|
Ludwig's angina
|
|
Lung abscess
|
|
Mandibular osteomyelitis
|
|
Necrotizing gingivitis
|
|
Necrotizing ulcerative mucositis (cancrum oris)
|
|
Nongonococcal tubo-ovarian abscess
|
|
Parametrial abscess
|
|
Pelvic peritonitis
|
|
Periodontitis
|
|
Peritonitis
|
|
Septic thrombophlebitis
|
|
Skene's glands infection
|
|
Vincent's angina
|
|
*With aerobes or other anaerobes.
|
|
Diagnosis
Clinical clues to the presence of anaerobic organisms include
Anaerobic infection should be suspected when any wound smells foul or when a Gram stain of pus from an infected site shows mixed pleomorphic bacteria. Only specimens from normally sterile sites should be cultured because commensal contaminants may easily be mistaken for pathogens.
Gram stains and aerobic cultures should be obtained for all specimens. Gram stain, particularly in Bacteroides infection, and cultures for all anaerobes may be falsely negative. Antibiotic sensitivity testing of anaerobes is exacting, and data may not be available for ≥ 1 wk after initial culture. However, if the species is known, sensitivity patterns can usually be predicted. Therefore, many laboratories do not routinely test anaerobic organisms for sensitivity.
Treatment
In established infection, pus is drained, and devitalized tissue, foreign bodies, and necrotic tissue are removed. Organ perforations must be closed or drained. Whenever possible, blood supply should be reestablished. Septic thrombophlebitis may require vein ligation as well as antibiotics.
Because anaerobic culture results may not be available for 3 to 5 days, antibiotics are started. Antibiotics sometimes work even when some of the bacterial species in a mixed infection are resistant to the antibiotic, especially if surgical debridement and drainage are adequate.
Oropharyngeal anaerobic infections may not respond to penicillin and thus require a drug effective against penicillin-resistant anaerobes (see below). Oropharyngeal infections and lung abscesses should be treated with clindamycin or a β-lactam/β-lactamase combination such as amoxicillin/clavulanate . In patients allergic to penicillin, clindamycin or metronidazole (plus a drug active against aerobes) is useful.
GI or female pelvic anaerobic infections are likely to contain obligate anaerobic gram-negative bacilli such as B. fragilis plus facultative gram-negative bacilli such as Escherichia
coli; antibiotic regimens must be active against both. Resistance of B. fragilis and other obligate anaerobic gram-negative bacilli to penicillins and 3rd- and 4th-generation cephalosporins occurs. However, the following drugs have excellent in vitro activity against B.
fragilis and are effective: metronidazole , carbapenems (eg, imipenem/cilastatin , meropenem , ertapenem ), β-lactam/β-lactamase combinations (eg, piperacillin/tazobactam , ampicillin/sulbactam , amoxicillin/clavulanate , ticarcillin /clavulanate), tigecycline, and moxifloxacin . No single regimen appears to be superior. Drugs that are somewhat less predictably active in vitro against B.
fragilis but are usually effective include clindamycin , cefoxitin , and cefotetan . All except clindamycin and metronidazole can be used as monotherapy because these drugs also have good activity against facultative anaerobic gram-negative bacilli.
Metronidazole is active against clindamycin -resistant B. fragilis, has unique anaerobic bactericidal activity, and usually avoids the pseudomembranous colitis sometimes associated with clindamycin . Concerns about its potential mutagenicity have not been of clinical consequence.
Because many regimens are available to treat GI or female pelvic anaerobic infections, use of a potentially nephrotoxic aminoglycoside (to cover enteric gram-negative bacilli) plus an antibiotic active against B. fragilis is no longer warranted.
Prevention
Before elective colorectal surgery, patients should have bowel preparation consisting of
Most surgeons give both oral and parenteral antibiotics. For emergency colorectal surgery, parenteral antibiotics are used alone. Examples of oral regimens are neomycin plus erythromycin or neomycin plus metronidazole ; these drugs are given no more than 18 to 24 h before the procedure. Examples of parenteral preoperative regimens are cefotetan , cefoxitin , or cefazolin plus metronidazole . Preoperative parenteral antibiotics control bacteremia, reduce secondary or metastatic suppurative complications, and prevent local spread of infection around the surgical site.
For patients with confirmed allergy or adverse reaction to β-lactams, one of the following regimens is recommended: clindamycin plus gentamicin , aztreonam , or ciprofloxacin ; or metronidazole plus gentamicin or ciprofloxacin .
Last full review/revision August 2009 by Joseph R. Lentino, MD, PhD
Content last modified August 2009
| 
